Researchers in Canada analyzed more than 5,400 records of patients with glucagon-like peptide 1 receptor agonist prescriptions, such as Type 2 diabetes drugs Ozempic (semaglutide) and Saxenda (liraglutide), and weight loss medication Wegovy (semaglutide). Weight management drug Contrave (bupropion/naltrexone), which is not a GLP-1, was used as a comparison.
They found that the “use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis, bowel obstruction and gastroparesis, but not biliary disease.”
Gastroparesis is when the stomach paralyzes as food digestion slows. The first reports of this side effect appeared in July, and by August, a lawsuit was filed against Novo Nordisk over stomach paralysis claims.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.